Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard T Carrick

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Circulation. Arrhythmia and Electrophysiology|December 13, 2024
Performance of ARVC Risk Calculators in (Likely) Pathogenic Plakophilin-2 Variant Carriers Without Definite ARVC DiagnosisSteven A Muller, Babken Asatryan, Brittney Murray, et al.
Circulation. Arrhythmia and Electrophysiology|July 2, 2026
Yield of Family Screening in Arrhythmogenic Right Ventricular Cardiomyopathy Without a Validated Genetic CauseSteven A Muller, Brittney Murray, Crystal Tichnell, et al.
Circulation. Arrhythmia and Electrophysiology|October 31, 2022
Longitudinal Prediction of Ventricular Arrhythmic Risk in Patients With Arrhythmogenic Right Ventricular CardiomyopathyRichard T Carrick, Anneline S J M Te Riele, Alessio Gasperetti, et al.
Circulation|June 17, 2025
Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular CardiomyopathySteven A Muller, Babken Asatryan, Alessio Gasperetti, et al.
JACC. Advances|June 17, 2026
Clinical Spectrum and Outcomes in Hypertrophic Cardiomyopathy With Apical Aneurysms: A Large Multicenter International CohortEthan J Rowin, Deacon Z J Lee, Mark V Sherrid, et al.
JACC. Clinical Electrophysiology|April 17, 2025
Long-Term Follow-Up Data on Flecainide Use as an Antiarrhythmic in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multicenter StudySean Gaine, Thomas Rolland, Babken Asatryan, et al.
Circulation|October 7, 2022
Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational StudyAlessio Gasperetti, Richard T Carrick, Sarah Costa, et al.
Medrxiv : the Preprint Server for Health Sciences|September 26, 2025
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter StudyOlives Nguyen, Jack Wiedrick, Daniele Massera, et al.
Journal of Cardiac Failure|March 3, 2026
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter StudyOlives Nguyen, Jack Wiedrick, Daniele Massera, et al.
European Heart Journal|January 9, 2024
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and EuropeRichard T Carrick, Corrado De Marco, Alessio Gasperetti, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Circulation. Arrhythmia and Electrophysiology|December 13, 2024
Performance of ARVC Risk Calculators in (Likely) Pathogenic Plakophilin-2 Variant Carriers Without Definite ARVC DiagnosisSteven A Muller, Babken Asatryan, Brittney Murray, et al.
Circulation. Arrhythmia and Electrophysiology|July 2, 2026
Yield of Family Screening in Arrhythmogenic Right Ventricular Cardiomyopathy Without a Validated Genetic CauseSteven A Muller, Brittney Murray, Crystal Tichnell, et al.
Circulation. Arrhythmia and Electrophysiology|October 31, 2022
Longitudinal Prediction of Ventricular Arrhythmic Risk in Patients With Arrhythmogenic Right Ventricular CardiomyopathyRichard T Carrick, Anneline S J M Te Riele, Alessio Gasperetti, et al.
Circulation|June 17, 2025
Family Screening in Relatives at Risk for Plakophilin-2-Associated Arrhythmogenic Right Ventricular CardiomyopathySteven A Muller, Babken Asatryan, Alessio Gasperetti, et al.
JACC. Advances|June 17, 2026
Clinical Spectrum and Outcomes in Hypertrophic Cardiomyopathy With Apical Aneurysms: A Large Multicenter International CohortEthan J Rowin, Deacon Z J Lee, Mark V Sherrid, et al.
JACC. Clinical Electrophysiology|April 17, 2025
Long-Term Follow-Up Data on Flecainide Use as an Antiarrhythmic in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multicenter StudySean Gaine, Thomas Rolland, Babken Asatryan, et al.
Circulation|October 7, 2022
Programmed Ventricular Stimulation as an Additional Primary Prevention Risk Stratification Tool in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational StudyAlessio Gasperetti, Richard T Carrick, Sarah Costa, et al.
Medrxiv : the Preprint Server for Health Sciences|September 26, 2025
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter StudyOlives Nguyen, Jack Wiedrick, Daniele Massera, et al.
Journal of Cardiac Failure|March 3, 2026
Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter StudyOlives Nguyen, Jack Wiedrick, Daniele Massera, et al.
European Heart Journal|January 9, 2024
Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and EuropeRichard T Carrick, Corrado De Marco, Alessio Gasperetti, et al.
Pageof 6